MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

PTC Therapeutics Inc

Deschisă

SectorSănătate

64.42 1.05

Rezumat

Modificarea prețului

24h

Curent

Minim

63.04

Maxim

65.15

Indicatori cheie

By Trading Economics

Venit

-931M

-65M

Vânzări

-997M

179M

P/E

Medie Sector

9.192

37.257

Marjă de profit

-36.254

Angajați

939

EBITDA

-1B

-35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+3.08% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1B

5.1B

Deschiderea anterioară

63.37

Închiderea anterioară

64.42

Sentimentul știrilor

By Acuity

25%

75%

73 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

PTC Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 iul. 2025, 16:40 UTC

Principalele dinamici ale pieței

PTC Therapeutics Gains on FDA Approval for Blood-Disorder Treatment

2 dec. 2024, 12:47 UTC

Principalele dinamici ale pieței

PTC Therapeutics Shares Jump on Pact With Novartis

Comparație

Modificare preț

PTC Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

3.08% sus

Prognoză pe 12 luni

Medie 65.87 USD  3.08%

Maxim 118 USD

Minim 44 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPTC Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

11

Cumpărare

5

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

40.81 / 50.39Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

73 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat